Philip Scheltens (Edmond Sadaka/Sipa via AP Images)
As venture funding in oncology flourishes, neuro has seen shallower pockets. A European investor wants to change that
Big Pharma has retreated from neuroscience over the past several years, abandoning or trimming back programs after facing setbacks in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.